Stoke Therapeutics (NASDAQ:STOK) Coverage Initiated at Leerink Partners

Analysts at Leerink Partners assumed coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a report released on Monday, StockNewsAPI reports. The firm set an “outperform” rating and a $18.00 price target on the stock. Leerink Partners’ price target points to a potential upside of 41.84% from the company’s current price.

Other analysts have also issued research reports about the company. Wedbush reissued an “outperform” rating and set a $17.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, July 11th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $20.83.

Stoke Therapeutics Stock Down 0.5 %

STOK opened at $12.69 on Monday. The stock has a market cap of $661.42 million, a PE ratio of -5.27 and a beta of 0.97. Stoke Therapeutics has a 52 week low of $3.35 and a 52 week high of $17.58. The business’s fifty day simple moving average is $13.75 and its 200 day simple moving average is $13.71.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The business had revenue of $4.83 million during the quarter, compared to the consensus estimate of $3.33 million. As a group, equities analysts anticipate that Stoke Therapeutics will post -2.1 earnings per share for the current year.

Insider Activity

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now directly owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics in the 2nd quarter valued at approximately $29,000. Nisa Investment Advisors LLC boosted its holdings in shares of Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after buying an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at $123,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Stoke Therapeutics in the 1st quarter worth about $141,000. Finally, The Manufacturers Life Insurance Company lifted its position in Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.